The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Johnson & Johnson (Inst); Medtronic (Inst); Stryker (Inst)
Prediction of postoperative recurrence by integrating preoperative ctDNA levels and tumor metastasis volume in patients (pts) with colorectal cancer (CRC) with resectable lung or liver metastasis.
 
Hidekazu Oyoshi
No Relationships to Disclose
 
Hideaki Bando
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Riu Yamashita
Consulting or Advisory Role - Takeda
 
Shun-ichiro Kageyama
No Relationships to Disclose
 
Satoshi Horasawa
No Relationships to Disclose
 
Masaki Nakamura
Honoraria - AstraZeneca; Varian Medical Systems
Consulting or Advisory Role - MSD
 
Takeshi Fujisawa
No Relationships to Disclose
 
Kento Tomizawa
No Relationships to Disclose
 
Atsushi Motegi
No Relationships to Disclose
 
Saori Mishima
No Relationships to Disclose
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Ono Yakuhin; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Takeda (Inst)
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Ichiro Takemasa
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
Research Funding - Chugai Pharma
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Guardant Health AMEA; Merck
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Masaki Mori
No Relationships to Disclose
 
Adham A Jurdi
Employment - Natera
Stock and Other Ownership Interests - Cardiff Oncology; natera
Speakers' Bureau - Natera
Travel, Accommodations, Expenses - Natera
 
Minetta C. Liu
Employment - Natera
Stock and Other Ownership Interests - Natera
Research Funding - Eisai (Inst); Exact Sciences (Inst); Genomic Health (Inst); GRAIL (Inst); Menarini Silicon Biosystems (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Genomic Health; GRAIL; Menarini Silicon Biosystems; Merck; Natera; Pfizer
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Genomedia (Inst); Molecular Health (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)